<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179659</url>
  </required_header>
  <id_info>
    <org_study_id>SP872</org_study_id>
    <nct_id>NCT01179659</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets Under Fed Conditions</brief_title>
  <official_title>A Pharmacokinetic Study to Assess the Bioequivalence of a Single-Dose of KUDCO and Wyeth Pharmaceuticals (Protonix) 40 mg Pantoprazole Sodium Delayed-Release Tablet When Administered to Healthy Adult Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kremers Urban Development Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kremers Urban Development Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to assess the single-dose bioequivalence of KUDCO's and Wyeth
      Pharmaceuticals' (Protonix) 40 mg pantoprazole sodium delayed-lease tablets, under fed
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized, fully replicated crossover, 2-sequence bioequivalence
      study under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration of drug substance in plasma)</measure>
    <time_frame>26 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)</measure>
    <time_frame>26 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (area under the concentration-time curve from time zero to infinity)</measure>
    <time_frame>26 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Protonix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole 40 mg DR Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet</intervention_name>
    <description>Single dose crossover BE study</description>
    <arm_group_label>Protonix</arm_group_label>
    <arm_group_label>Pantoprazole 40 mg DR Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, non-smoking (for at least 6 months) male or female volunteers, 18 - 55
             years of age.

          -  Weighed at least 52 kg for males and 45 kg for females and within 15% of their ideal
             weights (Table of &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company,
             1983).

          -  Medically healthy subjects with clinically normal laboratory profiles, vital signs,
             and ECG.

          -  Females of childbearing potential were either sexually inactive (abstinent) for 14
             days prior to the first dose and throughout the study, or using one of the following
             acceptable birth control methods:

               1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy) 6 months minimum.

               2. Intrauterine device (IUD) in place for at least 3 months.

               3. Barrier method (condom, diaphragm) with spermicide for at least 14 days prior to
                  the first dose and throughout the study.

               4. Surgical sterilization of the partner (vasectomy for 6 months minimum).

               5. Hormonal contraceptives for at least 3 months prior to the first dose of the
                  study.

          -  Gave voluntary written informed consent to participate in the study.

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

               1. Alcoholism or drug abuse within the past 2 years;

               2. Hypersensitivity or idiosyncratic reaction to pantoprazole, omeprazole, or any
                  other substituted benzimidazole proton-pump. inhibitors.

          -  Females who were pregnant or lactating.

          -  History of tobacco use or use of products containing nicotine (i.e., smoking cessation
             aids such as nicotine gum or patches) within the 6 months prior to the first dose.

          -  Subjects who tested positive at screening for human immunodeficiency virus (HIV)
             antibody screen, hepatitis B surface antigen screen (HbsAg), or hepatitis C antibody
             screen (HCV).

          -  Treatment with any known enzyme-altering drugs (barbiturates, phenothiazines,
             cimetidine, etc.) within 30 days prior to the first dose.

          -  Difficulty in swallowing medication or any gastrointestinal disease that would affect
             the drug absorption.

          -  Subjects who had been on a special diet (for whatever reason) during the 28 days prior
             to the first dose and throughout the study.

          -  Subjects who, through completion of the study, would have donated in excess of:

               -  500 mL of blood in 14 days;

               -  1500 mL of blood in 180 days;

               -  2500 mL of blood in one years.

          -  Subjects who participated in another clinical trial with 28 days prior to the first
             dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano morelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Saint-Laurent, Montreal</city>
        <state>Quebec</state>
        <zip>H4R 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gartano Morelli, MD</name_title>
    <organization>MDS Pharma Services</organization>
  </responsible_party>
  <keyword>Single dose crossover BE study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 12, 2010</submitted>
    <returned>September 8, 2010</returned>
    <submitted>June 23, 2011</submitted>
    <returned>July 22, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

